[HTML][HTML] 24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation

…, A Ohradanova-Repic, P Schatzlmaier, C Donner… - Journal of …, 2021 - Elsevier
Background & Aims 24-NorUrsodeoxycholic acid (NorUDCA) is a novel therapeutic bile
acid for immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (…

The late endosomal transporter CD222 directs the spatial distribution and activity of Lck

…, P Eckerstorfer, A Zwirzitz, C Donner… - The Journal of …, 2014 - journals.aai.org
The spatial and temporal organization of T cell signaling molecules is increasingly accepted
as a crucial step in controlling T cell activation. CD222, also known as the cation-…

[HTML][HTML] Dissecting mannose 6-phosphate-insulin-like growth factor 2 receptor complexes that control activation and uptake of plasminogen in cells

…, B Binder, S Lakatošová, C Donner… - Journal of Biological …, 2012 - ASBMB
The plasminogen (Plg) activation cascade on the cell surface plays a central role in cell
migration and is involved in a plethora of physiological and pathological processes. Its …

[HTML][HTML] Immune cell profiles and patient clustering in complex cases of interstitial lung disease

…, A Ohradanova-Repic, M Kramer, C Donner… - Immunology …, 2023 - Elsevier
Interstitial lung disease comprises numerous clinical entities posing significant challenges
towards a prompt and accurate diagnosis. Amongst the contributing factors are intricate …

The mannose 6-phosphate/insulin-like growth factor 2 receptor mediates plasminogen-induced efferocytosis

…, C Machacek, C Donner… - Journal of Leukocyte …, 2019 - academic.oup.com
The plasminogen system is harnessed in a wide variety of physiological processes, such as
fibrinolysis, cell migration, or efferocytosis; and accordingly, it is essential upon inflammation…

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

…, NK Ganguly, GB Nair, SK Bhattacharya, JD Clemens - The Lancet, 2009 - thelancet.com
Background Oral cholera vaccines consisting of killed whole cells have been available for
many years, but they have not been used extensively in populations with endemic disease. An …

[HTML][HTML] A cluster-randomized effectiveness trial of Vi typhoid vaccine in India

…, B Bhaduri, CJ Acosta, JD Clemens - … England Journal of …, 2009 - Mass Medical Soc
Background Typhoid fever remains an important cause of illness and death in the developing
world. Uncertainties about the protective effect of Vi polysaccharide vaccine in children …

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial

…, AL Lopez, TF Wierzba, JD Clemens - The Lancet infectious …, 2013 - thelancet.com
Background Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral
cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term …

[HTML][HTML] Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial

…, SK Bhattacharya, GB Nair, JD Clemens… - PLoS neglected …, 2011 - journals.plos.org
Background Killed oral cholera vaccines (OCVs) have been licensed for use in developing
countries, but protection conferred by licensed OCVs beyond two years of follow-up has not …

Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India

…, JL Deen, AL Lopez, J Clemens - Clinical Infectious …, 2013 - academic.oup.com
Background. We evaluated the herd protection conferred by an oral cholera vaccine using 2
approaches: cluster design and geographic information system (GIS) design. Methods. …